papillary RCC

• 

Savolitinib and durvalumab for metastatic papillary kidney cancer

By Sharon Deveson Kell|2023-03-23T09:27:27+00:0023 Mar 2023|Drug treatments|

In a phase 2 clinical trial, patients with metastatic papillary [...]

Read More

Comments Off on Savolitinib and durvalumab for metastatic papillary kidney cancer

• 

Savolitinib plus durvalumab for papillary kidney cancer

By Sharon Deveson Kell|2023-03-06T12:34:35+00:006 Mar 2023|Drug treatments|

In a recent study published in the Journal of Clinical [...]

Read More

Comments Off on Savolitinib plus durvalumab for papillary kidney cancer

• 

Real-world survival outcomes of metastatic papillary and clear cell kidney cancer

By Sharon Deveson Kell|2023-01-17T08:22:55+00:0017 Jan 2023|Drug treatments|

In this study, real world data is used to compare [...]

Read More

Comments Off on Real-world survival outcomes of metastatic papillary and clear cell kidney cancer

• 

Papillary type I vs type II renal cell carcinoma

By Sharon Deveson Kell|2022-06-28T08:44:46+00:0028 Jun 2022|Subtypes of RCC|

Papillary renal cell carcinoma (pRCC) is the second most common [...]

Read More

Comments Off on Papillary type I vs type II renal cell carcinoma

• 

EIKCS 2022: Treatment for non-clear cell kidney cancer subtypes

By Sharon Deveson Kell|2022-04-26T08:39:32+00:0026 Apr 2022|Drug treatments, Subtypes of RCC|

At the European International Kidney Cancer Symposium (EIKCS) in Antwerp, [...]

Read More

Comments Off on EIKCS 2022: Treatment for non-clear cell kidney cancer subtypes

• 

Biomarker for predicting disease recurrence in non-metastatic papillary kidney cancer

By Sharon Deveson Kell|2022-04-13T14:04:45+00:0013 Apr 2022|Subtypes of RCC|

A biomarker is a biological molecule found in blood, other [...]

Read More

Comments Off on Biomarker for predicting disease recurrence in non-metastatic papillary kidney cancer

• 

Telaglenastat plus cabozantinib or everolimus for advanced/metastatic kidney cancer

By Sharon Deveson Kell|2022-03-15T07:48:59+00:0015 Mar 2022|Drug treatments|

This phase 1 clinical trial looked at the safety, tolerability, [...]

Read More

Comments Off on Telaglenastat plus cabozantinib or everolimus for advanced/metastatic kidney cancer

• 

ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

By Sharon Kell|2021-02-15T10:03:32+00:0015 Feb 2021|Drug treatments|

A gene called MET codes for a protein called MET [...]

Read More

Comments Off on ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

• 

Patterns of metastases for clear cell, papillary and chromophobe RCC associated with survival

By Sharon Kell|2021-02-10T09:08:50+00:0010 Feb 2021|Subtypes of RCC|

A recent study published in JAMA Network Open looked at [...]

Read More

Comments Off on Patterns of metastases for clear cell, papillary and chromophobe RCC associated with survival

• 

Everolimus and bevacizumab for advanced papillary kidney cancer

By Sharon Kell|2020-10-30T09:00:31+00:0030 Oct 2020|Uncategorized|

In this phase 2 clinical trial, a combination of everolimus [...]

Read More

Comments Off on Everolimus and bevacizumab for advanced papillary kidney cancer